Jones Kertz & Associates Inc. Takes Position in Medtronic PLC $MDT

Jones Kertz & Associates Inc. acquired a new stake in Medtronic PLC (NYSE:MDT) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,398 shares of the medical technology company’s stock, valued at approximately $999,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC lifted its holdings in shares of Medtronic by 104.6% in the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after buying an additional 3,492,192 shares during the period. Schroder Investment Management Group lifted its holdings in shares of Medtronic by 78.3% in the third quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after buying an additional 3,307,211 shares during the period. Guinness Asset Management LTD acquired a new stake in shares of Medtronic in the third quarter valued at $275,556,000. Wellington Management Group LLP lifted its holdings in shares of Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock valued at $970,456,000 after buying an additional 2,658,981 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in shares of Medtronic by 2,297.7% in the fourth quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company’s stock valued at $241,179,000 after buying an additional 2,406,000 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. UBS Group reiterated a “neutral” rating and issued a $104.00 target price on shares of Medtronic in a report on Wednesday, February 4th. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Barclays boosted their target price on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Finally, Piper Sandler dropped their target price on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a report on Wednesday, April 1st. Sixteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.25.

Medtronic Stock Performance

Shares of MDT stock opened at $85.15 on Tuesday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $109.32 billion, a price-to-earnings ratio of 23.72, a P/E/G ratio of 2.24 and a beta of 0.75. The stock’s fifty day simple moving average is $91.18 and its 200-day simple moving average is $95.64. Medtronic PLC has a 1-year low of $79.93 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period last year, the company posted $1.38 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date was Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).